LEADERSHIP

Paul Hamelin was appointed President in November 2008 after joining us in May 2006 as Senior Vice President, Commercial Operations. From March 2006 until May 2006, Mr. Hamelin was Managing Director of Rosemont. From 2004 to 2005 Mr. Hamelin served as President and Chief Operating Officer at Algorx Pharmaceuticals. Prior to joining Algorx he held the positions of President and Chief Executive Officer of Elitra Pharmaceuticals, Inc. from 2002 to 2004 and Senior Vice President, Global Commercial Operations at Millennium Pharmaceuticals, Inc. from 2000 to 2002. Prior to Mr. Hamelin’s experience at specialty and biotech companies, for over 20 years he held senior management marketing, sales and commercial operations positions at several large pharmaceutical companies including Pharmacia/Searle, Abbott Labs and Eli Lilly.  He is also a Registered Pharmacist.

Philip K. Yachmetz, our Senior Vice President, General Counsel and Secretary, joined us in May 2004 and served as our Chief Business Officer from February 2006 to November 2008. Mr. Yachmetz was Senior Vice President – Corporate Strategy, General Counsel and Secretary from May 2004 until February 2006. Mr. Yachmetz joined us from Progenics Pharmaceuticals, Inc., where he held the position of Vice President, General Counsel and Secretary from 2000 until 2004. From 1998 to 2000 he served as Senior Vice President, Business Development, General Counsel and Secretary at CytoTherapeutics, Inc. (now StemCells, Inc.). He also founded and served in 1997 to 1998 as Managing Director of Millennium Venture Management, LLC, a business consulting and advisory firm to the pharmaceutical, healthcare, and high technology industry. From 1989 to 1996, he held legal positions of increasing responsibility at Hoffmann-La Roche Inc. Mr. Yachmetz is an attorney admitted to the bar in New Jersey and New York.

David joined us in February 2006 as Vice President Finance and Controller and was promoted to Vice President, Chief Financial Officer & Treasurer in February 2009. Through his career, Mr. Gionco has held various audit, corporate accounting, financial planning, finance and controller roles of increasing responsibility at companies including Medco, Merck & Co., Progenics Pharmaceuticals and Odyssey Pharmaceuticals, where he served as Acting Chief Financial Officer/Director of Finance and Controller before joining Savient. In addition, Mr. Gionco has seven years of financial auditing experience with a major public accounting firm. Mr. Gionco holds a B.S in Accounting from Fairleigh Dickinson University and an MBA from Rutgers University.